Abstract：
The role of 2-deoxy-2-[18F]fluoro-D-glucose Positron Emission Tomography/Computed Tomography (FDG PET/CT) in the management of prostate cancer (PCa) patients is increasingly recognised. However, its clinical role is still controversial. Many published studies showed that FDG PET/CT might have a prognostic value in the metastatic castration-resistant phase of the disease, but its role in other settings of PCa and, more importantly, its impact on final clinical management remains to be further investigated. We describe a series of six representative clinical cases of PCa in different clinical settings, but all characterised by a measurable clinical impact of FDG PET/CT on the patients\' management. Starting from their clinical history, we report a concise narrative literature review on the advantages and limitations of FDG PET/CT beyond its prognostic value in PCa. What emerges is that in selected cases, this imaging technique may represent a useful tool in managing PCa patients. However, in the absence of dedicated studies to define the optimal clinical setting of its application, no standard recommendations on its use in PCa patients can be made.
摘要：
2-脱氧-2-[18F]氟-D-葡萄糖正电子发射断层扫描/计算机断层扫描（FDGPET/CT）在前列腺癌（PCa）患者的治疗中的作用越来越被认可。然而,其临床作用仍有争议。许多已发表的研究表明，FDGPET/CT可能在该疾病的转移性去势抵抗阶段具有预后价值，但它在PCa和其他设置中的作用，更重要的是,其对最终临床管理的影响还有待进一步研究.我们描述了一系列不同临床环境中的6例PCa代表性临床病例，但所有这些都以FDGPET/CT对患者管理的可测量临床影响为特征。从他们的临床病史开始，我们报告了关于FDGPET/CT在PCa中超出其预后价值的优势和局限性的简明叙述性文献综述。出现的是，在选定的情况下，这种成像技术可能是治疗PCa患者的有用工具.然而,在没有专门的研究来定义其应用的最佳临床设置的情况下，无法就其在PCa患者中的使用提出标准建议.
